ANI Pharma (ANIP) Tops Q4 EPS Views; Issues FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ANI Pharmaceuticals (ANIP) PT Lifted to $79 at Guggenheim
February 19, 2015 12:52 PM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $79.00 (from $65.00) following Q4 results.
Chen commented, "Post ANIP's 4Q14 beat, we remain positive on ANIP shares, as we continue to believe a large... More
